WO2000026358A1 - Sequence d'insertion de selenocysteine - Google Patents
Sequence d'insertion de selenocysteine Download PDFInfo
- Publication number
- WO2000026358A1 WO2000026358A1 PCT/JP1999/005984 JP9905984W WO0026358A1 WO 2000026358 A1 WO2000026358 A1 WO 2000026358A1 JP 9905984 W JP9905984 W JP 9905984W WO 0026358 A1 WO0026358 A1 WO 0026358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- selenoprotein
- dna
- txri
- utr
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- the present invention relates to a base sequence called selenosysteine-insertion sequence (hereinafter abbreviated as SECIS).
- SECIS selenosysteine-insertion sequence
- Selenoprotein is a generic term for proteins containing Se (selenium), one of the essential trace elements, as Secys (serenocystine). Selenocistine has a structure in which Se is a constituent element instead of cysteine S. Secys has also been reported to have radioprotective and anticancer effects.
- Glucose-thione peroxidase which reduces and scavenges the reactive oxygen species hydroperoxide (-00H) in a glucane-thione-thioredoxin-dependent manner, as a protein containing Secys, thyroid hormone (thyroxine) precursor Type I tetrachodothyronine dehydrogenase, which converts body T4 to activated T3.
- thyroxine thyroid hormone
- Type I tetrachodothyronine dehydrogenase
- TxR human thioredoxin reductase
- Secys is the 21st amino acid that can be translated and has a unique biosynthetic mechanism encoded by the stop codon UGA.
- 3' UTR 3 'untranslated region located downstream of it.
- TxR is a selenoprotein in Q It is clear that this is one of Human TxR contains Secys as a constituent amino acid at the C-terminus, similar to the TxR of cypress.
- 3 'UTR of the cDNA the existence of a region corresponding to SECIS described above has been clarified (Pamera Y. et al., Cloning and sequencing of a human thioredoxin reductase, FEBS Letters, 373, 5-9, 1995, Koishi R. et al. Cloning and characterizati on of a novel oxidreductase KDRF from human bone marrow-derived stromal cell lline KM-102., JBC, 272, 2570-2577, 1997).
- a stem-loop structure is produced in the region consisting of thousands of UTRs, and the UGA present in the translation region is recognized not as a termination codon but as a selenocystine codon.
- selenocistine in It is believed that.
- An essential region for inserting selenocysteine into the translation region is a nucleotide sequence called SECIS. It can be understood that for proteins in which selenocysteine has a significant effect on enzymatic activity, the 3 'UTR must be accompanied by SEC IS when expressed.
- SECIS requires a long base sequence of several thousand b as an essential region. Long nucleotide sequences can be a hindrance in vectors with limited insertion sequences. Also, when the entire cDNA including the transcription region becomes large, there is a concern that the efficiency of amplification by PCR may decrease. Alternatively, mutations may be introduced during amplification by PCR. Therefore, it is desired to provide a new SECIS capable of minimizing the number of constituent bases as much as possible and ensuring the insertion of selenocysteine in the translation region. Disclosure of the invention
- An object of the present invention is to provide a novel SECIS, a vector for expressing selenoprotein using the SECIS, and a use thereof.
- TxRI I and TxRI I 3 respectively, from the human placenta cDNA library, (Collectively referred to as TxRI Is) was isolated, and a patent application was filed as Japanese Patent Application No. 10-310422.
- the genes encoding these novel proteins were isolated during the process of screening for a binding factor to XIAP (X-1 inked inhibitor of apoptosis protein), one of the apoptosis-inhibiting proteins in humans.
- the present inventors analyzed the amino acid sequence deduced from the cDNA, and found that the same amino acid sequence as Cys-Secys-Gly-stop codon (T) exists near the C-terminus as in the known TxR. (SEQ ID NO: 3, and SEQ ID NO: 5).
- the SECIS responsible for the insertion of this selenocysteine was compared to the SECIS reported for the other selenoproteins described above, and to TxRI I
- the present invention has been clarified by comparing the 3 ′ UTRs and the present invention has been completed. That is, the present invention relates to the following SECIS, vectors for expression of selenoproteins using the same, and uses thereof.
- DNA comprising the nucleotide sequence of SEQ ID NO: 1.
- nucleotide sequence of SEQ ID NO: 1 one or more nucleotides consist of a substituted, deleted, added, and / or inserted nucleotide sequence, and are included in a translation region located upstream thereof. DNA capable of inserting selenocystine into the TGA codon.
- a vector for selenoprotein expression comprising the following elements:
- a method for producing a selenoprotein comprising a step of culturing the transformant according to claim 1 and recovering selenoprotein.
- SECIS of the present invention can be chemically synthesized according to the nucleotide sequence shown in SEQ ID NO: 1. Alternatively, it can be obtained from human TxRI I or human TxRI I 3 cDNA. These cDNAs are contained in CL0NTECH's Human Placenta MATCHMAKER cDNA Library, a commercially available placenta cDNA library. Therefore, it is easy to obtain a necessary region by performing PCR using a primer capable of specifically amplifying the necessary region.
- the nucleotide sequences of human TxRI I and human TxRI I5 cDNA are shown in SEQ ID NO: 2 and SEQ ID NO: 4, respectively.
- the SECIS according to the present invention has a nucleotide sequence as long as it can insert selenocystin into the TGA codon to be translated into selenocystine contained in the translation region of selenoprotein located upstream thereof. Mutations can be tolerated. Specifically, the stem-loop structure of the mRNA transcribed based on the DNA of SEQ ID NO: 1 (Fig. 4) plays an important role in selenocystine insertion. Therefore, mutations in the nucleotide sequence that do not significantly alter this structure are included in the present invention. For example, in the base sequence of SEQ ID NO: 1, one or more bases are substituted or deleted.
- a DNA comprising a lost, added, and / or inserted nucleotide sequence and capable of inserting selenocystine into the TGA codon contained in the translation region located upstream thereof is included in the present invention. It is also possible to hybridize under stringent conditions to MA consisting of the nucleotide sequence of SEQ ID NO: 1 and insert selenocysteine into the TGA codon contained in the translation region located upstream thereof. DNA is also included in the present invention. Thus, homologs from non-human species constitute the SEC IS of the present invention. Many sequences that can hybridize to a specific sequence under stringent conditions are likely to have activities similar to the functions provided by the specific sequence.
- hybridization conditions include 5xSSC and 25 ° C in the absence of formamide. Preferably, it is performed at 25 ° C. in 6 ⁇ SSC, 40% formamide. More preferably, it is carried out at 40 ° C with 5xSSC, 50% formamide.
- Whether a MA with a certain base sequence can insert selenocysteine into the TGA codon contained in the translation region located upstream of the MA depends on the presence of the selenoprotein downstream of the DNA encoding the selenoprotein. It can be confirmed by examining the amino acid sequence of the expression product of the expression vector in which DM is placed. In other words, if it is translated as a protein having the expected molecular weight, it can be considered that selenocysteine has been inserted. Alternatively, when selenocysteine constitutes the active center, the introduction of selenocysteine can be confirmed by examining the activity of the protein. For example, TXRI Is or the like is used as the selenoprotein.
- the SECIS thus obtained inserts selenocysteine into UGA upon translation of the sequence by linking the selenoprotein downstream of the cDNA encoding it.
- the position of the SECIS according to the invention relative to the translation region is arbitrary. sand That is, SECIS can be linked or inserted at any position in the former 3 'UTR.
- the entire cDNA including the 3 ′ UTR can be shortened, it is desirable not to leave an unnecessary 3 ′ UTR.
- by changing the position of the stem-and-loop structure it is possible to control the selenocistin uptake efficiency.
- the selenocysteine is introduced by the original cDNA by joining the SECIS of another selenoprotein to the 3 'UTR instead of the original SECIS.
- the activity is four times higher than the activity (Maria J. et al. Functional characterization of the eukaryotic SECIS element which direct selenocysteine insertion at UGA. EMBO, 12, 3315-3322, 1993).
- the SECIS according to the present invention can be arranged to achieve efficient selenocysteine introduction.
- the SECIS of the present invention can be incorporated in the expression vector in advance together with the control region necessary for protein expression, and used as a selenoprotein expression vector.
- a vector expressing a complete protein containing selenocysteine for any selenoprotein can be obtained. It can be easily constructed.
- the previously reported SECIS has been shown to function even if the gene located upstream is replaced by another selenoprotein (Maria J. et al.
- the SECIS of the present invention also exhibits selenocystin-introducing activity not only for TxRI I shin 5 from which it is derived, but also for other selenoproteins.
- SECIS according to the present invention is capable of expressing selenocysteine in the expression of selenoprotein in animal cells as a host, regardless of the type of protein. Introducing activity can be shown.
- the control region necessary for protein expression refers to a promoter enhancer.
- TxR selenocystine has been shown to play an important role in its reducing activity. Since human TxR and TxRI Is also have the amino acid sequence of Cys-Secys-Gly-stop codon, which is a structure that supports the reduction activity of pesticide TxR, selenocysteine also has a large effect on enzyme activity. It is estimated. SECIS is a special nucleotide sequence required for translation of selenocystin, and is an important element in the expression of these proteins.
- the present invention provides a DNA capable of hybridizing to SEQ ID NO: 1 and having a chain length of 15 nucleotides or more.
- the DNA according to the present invention is useful as a probe for detecting SECIS or a primer for amplifying SECIS.
- SECIS single-chain polypeptide
- the gene encoding a protein that contains selenocystin as the constituent amino acid may be strongly expressed in that cell. Suggests gender. This indicates that the DNA that hybridizes to SECIS of the present invention can be used to identify unknown selenoproteins.
- the analysis of mRNA is a method usually performed, for example, as a northern processing system.
- the DNA according to the present invention is used as a primer, the nucleotide sequence can be amplified using SECIS mMA or genomic DNA as type III.
- the DNA used for these purposes should have a chain length of at least 15 nucleotides in order to enable hybridization under stringent conditions. Preferably, it is 15-200 nucleotides, and more preferably, it is an oligonucleotide consisting of 25-100 nucleotides.
- the nucleotide sequence that achieves specific hybridization does not necessarily need to be completely complementary to the target nucleotide sequence of interest. Stringent Sequence variation is allowed provided that the required specificity is achieved under the conditions. Oligonucleotides having a set base sequence can be obtained by chemical synthesis.
- a labeling component such as an enzyme, a fluorescent substance, a luminescent substance, or a radioisotope can be added to these oligonucleotides as necessary.
- a method of direct chemical bonding is known.
- the oligonucleotide can be indirectly bound by labeling the oligonucleotide with a ligand such as hapten or biotin, and by a receptor such as an antibody or biotin recognizing this ligand.
- the present invention provides an antisense DNA for the DNA shown in SEQ ID NO: 1 or a part thereof.
- SECIS according to the present invention plays an important role in selenoprotein expression, and its activity is supported by a stem-loop structure (FIG. 4) formed in mRNA.
- FOG. 4 stem-loop structure
- an antisense sequence that interferes with this structure will inhibit translation of the selenoprotein located upstream.
- SECIS according to the present invention is derived from TxRI Is mRNA
- the antisense sequence according to the present invention functions as a specific expression inhibitor for TxRI Is.
- the present invention also provides a method for screening a selenoprotein expression regulator. That is, a host cell transformed by the selenoprotein expression vector according to the present invention enables screening of an expression controlling substance.
- a candidate compound for an expression controlling substance When the cells are contacted with a candidate compound for an expression controlling substance, the TxR activity in the cells or in the culture supernatant is increased or decreased depending on the expression controlling activity of the candidate compound. Therefore, by comparing this change in activity with an untreated control, it is possible to screen for a regulatory substance that inhibits or promotes expression.
- a mammalian cell line such as 293T is desirable. Brief description of the figure FIG.
- FIG. 1 is a graph showing the TxR activity of the recombinant TxRI or TxR II as measured by the DTNB assay.
- the vertical axis indicates the absorbance at 412 nm, and the horizontal axis indicates the reaction time.
- (a)-(g) indicate expression products of the following vectors.
- FIG. 2 is a graph showing TxR activity measured by TxRI or TxRII recombinant recombinant insulin assay.
- the vertical axis indicates the relative activity (%) when the activity of TxRII was defined as 100, and the horizontal axis indicates the type of vector.
- (A)-(g) indicate expression products of the following vectors.
- FIG. 3 is a diagram schematically showing the structure of (b)-(g) obtained by adding an artificial mutation to 3′UTR among the vectors expressed in the examples.
- FIG. 4 is a diagram schematically showing a stem-loop structure composed of SECIS according to the present invention shown in SEQ ID NO: 1 translated into mRNA.
- TxRI Is In order to prove that the active center of TxRI Is is a C-terminal selenocystine (SeCys) residue and that its 3 'UTR is essential for recognizing the UGA codon as SeCys, the following 4 types A TxMI expression vector was constructed. To prove that the 3 'UTR of TxRI I is also useful for other selenoproteins, the 3' UTR of TxRI I was replaced with the 3 'UTR of human TxRI already reported. An integrated TxRI expression vector was constructed. Figure 3 shows the structure of fflRNA generated by transcription of these vectors.
- TxRI I The entire gene including the 3'-UTR of TxRI I (hereinafter referred to as TxRI I) was subcloned into pCMV6myc, a mammalian cell expression vector.
- the pCMV6myc vector is a vector having pcDNA3 (Invitrogen) as a basic skeleton, and incorporating the amino acid sequence called Mickle Gepitope into the Hindi II and BamHI sites of its multicloning site (MCS) by repeating it six times.
- MCS multicloning site
- the gene integrated into the MCS of this vector is transcribed or translated as a gene product with a mix at the N-terminal. Therefore, it is possible to use an antibody specific to the Mic tag to perform detection using an estamplot, etc., or to purify by immunoprecipitation.
- the gene sequence excluding 3, -UTR of TxRI I o was obtained by PCR using PACT2-TxRI I hyperplasmid DNA as type III using the following primers.
- the 3 'primer was designed so as to obtain a cDNA in which the last stop codon was deleted from the amino acid sequence T-V-T-G-C-Se-Cys-G-stop for the future experiment.
- the PCR reaction was carried out using GeneAmp PCR System 2400 (PERKINELMER) according to the following program.
- the PCR product was treated with restriction enzymes BainH I and Xho I, separated by agarose electrophoresis, and purified according to a conventional method.
- the vector, pCMV6myc was treated with the restriction enzymes BamH I and Xho I, separated by agarose electrophoresis, and purified according to a conventional method. After ligation, both were transformed into E. coli strain DH5. Plasmid DNA was recovered from the obtained colonies using the alkali-SDS method. Transfer the recovered plasmid DNA to a suitable restriction enzyme. Then, the target PCR product was incorporated into the vector by agarose gel electrophoresis.
- the recovered DNA was purified by the polyethylene glycol precipitation method, and the PCR product in the vector was confirmed by a fluorescent sequencer (PERKINELMER) based on the Sanger method.
- a fluorescent sequencer PERKINELMER
- a plasmid DNA pCMV6myc-TxRI I A3'UTR in which the gene sequence excluding TxRI I and 3, -UTR was integrated into the pCMV6myc vector was obtained.
- PACT2 Primer located upstream of MCS of vector.
- the PCR reaction was carried out using GeneAmp PCR System 2400 (PERKINELMER) according to the following program.
- the PCR product was treated with restriction enzymes BamH I and Xho I, separated by agarose electrophoresis, and purified according to a conventional method.
- Vector pCMV6myc was treated with restriction enzymes BamH I and Xho I, separated by agarose electrophoresis, and purified according to a conventional method. After ligation of both, E. coli strain DH5 was transformed. Plasmid DNA was purified from the obtained colonies by a conventional method, and the PCR product in the vector was confirmed by a fluorescent sequencer (PERKINELMER) based on the Sanger method.
- PERKINELMER fluorescent sequencer
- the following primers were synthesized from the DNA sequence shown in SEQ ID NO: 2 (Japanese Patent Application No. 10-310422), and the 3 'UTR sequence of TxR II was obtained by PCR.
- the primer was used to amplify 358b of SEQ ID NO: 2 from 1573 to 1930.
- the 4th to 9th bases (TCTAGA) at the end are restriction enzyme Xba I sites.
- the 4th to 9th bases (TCTAGA) at the end are restriction enzyme Xba I sites.
- Plasmid pACT2-TxRII into which the full-length cDNA containing TTR3 and UTR was inserted The 3, UTR was used as a template DNA and amplified by PCR.
- the PCR reaction was performed using GeneAmp PCR System2400 (PEMINELMER) according to the following program.
- the amplified DNA fragment was confirmed by 1% agarose electrophoresis.
- This MA fragment was treated with the restriction enzyme Xbal.
- the DNA fragment treated with the restriction enzyme was electrophoresed on 1% agarose, cut out, and purified by a glass matrix method (BI0101, GeneClean).
- pSL-1180 (amersham pharmacia biotech) was treated with restriction enzyme XbaI, and then treated with alkaline phosphatase and purified. These were ligated according to a conventional method. This was transformed into Escherichia coli strain DH5 according to a conventional method, and plasmid DNA was purified from the obtained colonies by the polyethylene glycol precipitation method.
- PCR product in the vector was subjected to fluorescence sequencing (PERKINELMER) based on the Sanga method. Confirmed by.
- plasmid DNA of pSL-3 ′ UTR in which the 3 ′ UTR sequence of the human TxRI I gene was integrated into the pS-1180 vector was obtained.
- the pSL-3 'UTR was treated with the restriction enzyme XbaI, and the 3' UTR of TxRI I was cut out.
- pCV6myc-TxRII and ⁇ 3, UTR were treated with restriction enzyme XbaI and then treated with alkaline phosphatase. These were ligated according to a conventional method, transformed into Escherichia coli strain DH5, and plasmid MA was purified from the obtained colonies by polyethylene glycol precipitation, and the PCR product in the vector was subjected to the Sanger method. And confirmed by fluorescence sequencer (PERKINELMER). As a result, pCMV6myc-TxRI I «3 'UTR AS was obtained in which TxRI I, 3 and UTR were integrated in the opposite direction (antisense) downstream of TxRI I, 3, UTR. 5. Construction of pCMV6myc-TxRI I Cys3, UTRsens and AS
- the pSL-3 'UTR was treated with the restriction enzyme XbaI, and the 3' UTR of TxRI I was cut out.
- pCMV6myc-TxRI I aCysA 3 ′ UTR was treated with a restriction enzyme XbaI and then treated with alkaline phosphatase. After ligating them according to the conventional method, they were transformed into E. coli strain DH5, and the plasmid DNA was purified from the obtained colonies by polyethylene glycol precipitation, and the PCR products in the vector were subjected to the Sanga method. Fluorescent sequencer-(PERKINELMER). As a result, pCMV6myc- ⁇ a Cys3 'UTRsens was obtained, in which the 3, UTR of TxRI I was integrated in the forward direction (sense) downstream of the CysA 3' UTR of TxRI I.
- the following primer for PCR was synthesized from the previously reported DNA sequence (GenBank accession number D88687) of human redoxin reductase 1 (hereinafter abbreviated as TxRI). 3. The primers were designed for future experiments so that a cDNA with the last stop codon removed from the C-terminal amino acid sequence L-Q-A-G-C-SeCys-G-stop was obtained.
- PCR reaction Plasmid DNA purified from Human Placenta MATCHMAKER cDNA Librar purchased from CLONTECH was used as type I DNA, and the full-length human TxRI gene was amplified by PCR. The PCR reaction was performed using the following program using GeneAmp PCR System 2400 (PERKINELMER).
- the amplified DNA fragment was confirmed by 1% agarose electrophoresis.
- This DNA fragment was treated with restriction enzymes BamH I and Xho I.
- the MA fragment treated with the restriction enzyme was electrophoresed on 1 agarose, excised, and purified by the glass matrix method (BI0101, GeneClean).
- the pCMV6myc-flag vector uses pcDNA3 (Invitrogen) as the basic backbone, and incorporates a sequence consisting of a repeat of an amino acid sequence called Mike gepitope six times into the HindIII and BamHI sites of its multicloning site (MCS). It is an Xhol and Xbal site downstream of which an amino acid sequence called flagepitope is incorporated. Therefore, a gene integrated between a Mic tag and a Flag tag is expressed as a gene product in which the Mic tag is bound to the N-terminal and the Flag tag is bound to the C-terminal.
- such a tag When there is no antibody against the gene product incorporated into the MCS, such a tag can be detected with an antibody against such a mix-and-flag flag, and such tags are widely used in various expression systems.
- the recovered DNA was purified by the polyethylene glycol precipitation method, and the PCR product in the vector was confirmed by a fluorescent sequencer (PERKINELMER) based on the Sanger method.
- a fluorescent sequencer PERKINELMER
- the pSL-3 'UTR was treated with the restriction enzyme XaI, and the 3' UTR of TxRI I was cut out.
- pCMV6myc-TxRI-flag was treated with restriction enzyme XbaI and then treated with alkaline phosphatase. These were ligated according to a conventional method. This was transformed into Escherichia coli strain DH5 according to a conventional method, and plasmid DNA was purified from the obtained colonies by polyethylene glycol precipitation, and the PCR product in the vector was subjected to fluorescent sequencing using the Sanger method. (PERKINELMER). As a result, pCMV6myc-TxRI-flag-3 'UTR was obtained, in which TxRI I and 3, UTO were integrated in the forward direction (sense) downstream of the TxRI gene.
- the mammalian cell expression plasmids (a) to (g) were transformed into cultured cells 293T derived from human fetal kidney cells by the Lvov :! method according to a conventional method. 48 hours after the transformation, the cells were collected and a cell extract was prepared. To this was added protein A sepharose conjugated with anti-MYC monoclonal antibody, and the mixture was gently stirred at 4 ° C for 2 hours.
- the MYC- night fusion protein bound to the protein A sepharose bound with the anti-MYC monoclonal antibody was precipitated by centrifugation, the supernatant was removed, and the NETN buffer (10 mM Tris-HCl, ImM EDTA, 0.5% NP-40, Washed several times with 150 mM NaCl). The supernatant was completely removed and diluted with 100 mM potassium phosphate pH 7.0, 10 mM EDTA, 0.2 mg / ml bovine serum albmin.
- the activity of thioredoxin reductase was measured by the following two methods according to a conventional method (Holmgren, A. et al. Methods Enzymol. 252: 199, 1995).
- the DNTB assay is a method for measuring TNB generated from DTNB by TxR activity based on the following reaction formula, based on absorption at a wavelength of 412 nm.
- the purified Mic tag fusion protein (1 to 50 zl) was added to Assay buffer 11 to make a total volume of 1.0 ml.
- the absorbance at 412 nm was measured at 25 ° C for 20 minutes. The results are shown in FIG.
- the purified mix protein (l-50z1) was added to Atsushi buffer-12 to make a total volume of 1.0 ml.
- NADPH oxidation was measured at 340 nm absorbance at 30 ° C for 5 minutes. Trx is reduced by TxR activity, and reduced Trx further promotes insulin reduction. At this time, TxR activity can be measured from the amount of oxidized NADPH.
- the amount of oxidized NADPH was calculated by the following formula. The relative value of the expression product by each vector when the activity of TxRI I was set to 100% is shown in the graph (Fig. 2).
- the SECIS of the present invention ensures that selenoproteins Achieve quality translation.
- a value of less than 360b is a very small number compared to the well-known SEC IS, for example, which amounts to several thousand b. With this number of bases, there is no inconvenience as an insert of the vector under normal conditions. It is also easy to synthesize SECIS itself.
- the SECIS of the present invention is a sequence having a broad activity that acts universally on not only TxRI Is originally derived, but also on selenoproteins in general.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99951123A EP1126026A4 (en) | 1998-10-30 | 1999-10-28 | INSERTION SEQUENCE WITH SELENOCYSTONE |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31042298 | 1998-10-30 | ||
JP10/310422 | 1998-10-30 | ||
JP10/325344 | 1998-11-16 | ||
JP32534498 | 1998-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000026358A1 true WO2000026358A1 (fr) | 2000-05-11 |
Family
ID=26566309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/005984 WO2000026358A1 (fr) | 1998-10-30 | 1999-10-28 | Sequence d'insertion de selenocysteine |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1126026A4 (ja) |
WO (1) | WO2000026358A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916159B2 (en) | 2007-04-02 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
-
1999
- 1999-10-28 EP EP99951123A patent/EP1126026A4/en not_active Withdrawn
- 1999-10-28 WO PCT/JP1999/005984 patent/WO2000026358A1/ja not_active Application Discontinuation
Non-Patent Citations (7)
Title |
---|
GASDASKA P. Y. ET AL.: "Cloning and Sequencing of a Human Thioredoxin Reductase", FEBS LETTERS, vol. 373, 1995, pages 5 - 9, XP002925831 * |
GASDASKA P. Y. ET AL.: "Cloning, Sequencing and Functional Expression of a Novel Human Thioredoxin Reductase", FEBS LETTERS, vol. 442, no. 1, January 1999 (1999-01-01), pages 105 - 111, XP002925834 * |
KOISHI R. ET AL.: "Cloning and Characterization of a Novel Oxidoreductase KDRF from a Human Bone Marrow-derived Stromal Cell Line KM-102", J. BIOL. CHEMISTRY, vol. 272, no. 4, 1997, pages 2570 - 2577, XP002925832 * |
MIRANDA-VIZUETE A. ET AL.: "Human Mitochondrial Thioredoxin Reductase: cDNA Cloning, Expression and Genomic Organization", EUR. J. BIOCHEM., vol. 261, no. 2, April 1999 (1999-04-01), pages 405 - 412, XP002925835 * |
See also references of EP1126026A4 * |
STADTMAN T. C.: "SELENOCYSTEINE", ANNU. REV. BIOCHEMISTRY, vol. 65, 1996, pages 83 - 100, XP002925830 * |
SUN Q.-A. ET AL.: "Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases", J. BIOL. CHEM., vol. 274, no. 35, 27 August 1999 (1999-08-27), pages 24522 - 24530, XP002925833 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916159B2 (en) | 2007-04-02 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
Also Published As
Publication number | Publication date |
---|---|
EP1126026A1 (en) | 2001-08-22 |
EP1126026A4 (en) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU764571B2 (en) | 5' ESTs and encoded human proteins | |
Gawienowski et al. | Calmodulin isoforms in Arabidopsis encoded by multiple divergent mRNAs | |
CA2297109A1 (en) | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues | |
US5783384A (en) | Selection of binding-molecules | |
WO2019228353A1 (zh) | Adh蛋白家族突变体及其应用 | |
Meng et al. | Cloning and identification of a novel cDNA coding thioredoxin-related transmembrane protein 2 | |
EP1141301A2 (en) | Sequence-determined dna fragments and corresponding polypeptides encoded thereby | |
CN1643148A (zh) | 小鼠精子形成基因、人男性不育关连基因、以及利用该基因的诊断系统 | |
Lee et al. | Cloning of Human Brain and Mouse Brain cDNAs Coding for S1, the Second Member of the Mammalian Elongation Factor-1 alpha Gene Family: Analysis of a Possible Evolutionary Pathway | |
WO1995027057A1 (fr) | GENE CODANT LA PROTEINE DE LIAISON IgG-Fc | |
WO2000026358A1 (fr) | Sequence d'insertion de selenocysteine | |
CN114774399B (zh) | 一种人工改造脱氨酶辅助的dna中5-羟甲基胞嘧啶修饰单碱基分辨率定位分析方法 | |
Javaud et al. | Ancestral exonic organization of FUT8, the gene encoding the α6-fucosyltransferase, reveals successive peptide domains which suggest a particular three-dimensional core structure for the α6-fucosyltransferase family | |
Andreoni et al. | Structure of the 5′ region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA | |
BAGNARESI et al. | Cloning and characterization of a maize cytochrome-b5 reductase withFe3+-chelate reduction capability | |
CA2367468C (en) | Rheumatoid arthritis gene and method for diagnosing rheumatoid arthritis | |
Zhouravleva et al. | Evolution of translation termination factor eRF3: is GSPT2 generated by retrotransposition of GSPT1's mRNA? | |
JPH0638771A (ja) | ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法 | |
Lau et al. | Cloning and characterization of chicken growth hormone binding protein (cGHBP) | |
Choi et al. | Genomic cloning and characterization of mitochondrial elongation factor Tu (EF-Tu) gene (tufM) from maize (Zea mays L.) | |
EP1758933B1 (en) | Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera | |
JP4193986B2 (ja) | ガンマグルタミルシステインの生産方法 | |
Aqua et al. | Characterization and expression of a cDNA specifying subunit VIIc of bovine cytochrome c oxidase | |
CA2592351A1 (en) | Transcriptional inhibitor for human k-ras gene | |
Huo et al. | Molecular cloning, identification and characteristics of a novel isoform of carbamyl phosphate synthetase I in human testis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 579730 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951123 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951123 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09830646 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999951123 Country of ref document: EP |